Log in to search using one of your social media accounts:

 

Self-Destructive Behavior among Full-Donor Blood and Marrow Grafts and the Association with Long-Term Graft Function
Research will always bring new insights and new treatment options for well-established clinical conditions. A study in this issue of Biology of Blood and Marrow Transplantation presents interesting similarities in the biology and treatment of patients with late graft failure and acquired aplastic anemia: Maruyama et  al report a retrospective single center cohort of 14 patients with late graft failure, defined as at least two cytopenic cell lines, and full donor chimerism1. In this cohort, the authors investigated the presence of previously established markers for immune-mediated bone marrow failure2, 3. (Source: Biol...
Source: Biology of Blood and Marrow Transplantation - November 20, 2017 Category: Hematology Authors: Richard F. Olsson Source Type: research

Individualizing Optimal Dosing of Anti-Thymocyte Globulin in Allogeneic Hematopoietic Cell Transplantation
Chronic graft vs. host disease (cGVHD) remains one of the major causes of treatment failure following allogeneic hematopoietic cell transplantation (HCT) as it results in considerable morbidity and mortality (1). The burden of cGVHD continues to increase with widespread use of peripheral grafts and unrelated donors demanding new approaches to curtail this challenge in future transplants (2). Allo-reactive lymphocytes within the graft are major players thus attempts at T-cell depletion have been a great area of interest. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Shahrukh Hashmi Source Type: research

Impact of Human Leukocyte Antigen (HLA) Alleles on Outcomes of Allogeneic Transplantation for B-Cell Non-Hodgkin Lymphomas: a Center for International Blood and Marrow Transplant Research Analysis
Conclusions are limited by the retrospective design and patient heterogeneity (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Basem M. William, Tao Wang, Michael D. Haagenson, Katharina Fleischhauer, Michael Verneris, Katharine C. Hsu, Marcos J. de Lima, Marcelo Fernandez-Vi ña, Stephen R. Spellman, Stephanie J. Lee, Brian T. Hill Source Type: research

Influence of Age on Acute and Chronic GVHD in Children Receiving HLA-Identical Sibling BMT for Acute Leukemia: Implications for Prophylaxis.
• Relapse remains the major cause of mortality of hematopoietic cell transplantation for pediatric acute leukemia• The intensity of immunosuppression may affect the risk of relapse• Acute graft versus host disease rates have decreased significantly over time among matched sibling donor transpl ants• Children 2-12 years are at very low risk for acute and chronic graft versus host disease thus may be good candidates for trials of reduced prophylaxis.• These findings should be validated before clinical application (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Muna Qayed, Tao Wang, Michael T. Hemmer, Stephen Spellman, Mukta Arora, Daniel Couriel, Amin Alousi, Joseph Pidala, Hisham Abdel-Azim, Mahmoud Aljuf, Mouhab Ayas, Menachem Bitan, Mitchell Cairo, Sung Won Choi, Christopher Dandoy, David Delgado, Robert Pet Source Type: research

Risk Assessment in Adult T-Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation
• Previously examined factors associated with HCT, were not prognostic.• A total of 824 patients were retrospectively examined in this study.• HCT-CI is useful pre-transplant prognostic factors for patients with ATL.• Newly developed ATL HCT-PI may have better prognostic value for patients w ith ATL. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Makoto Yoshimitsu, Ryuji Tanosaki, Koji Kato, Takashi Ishida, Ilseung Choi, Yoshifusa Takatsuka, Takahiro Fukuda, Tetsuya Eto, Michihiro Hidaka, Naoyuki Uchida, Toshihiro Miyamoto, Yasuhiro Nakashima, Yukiyoshi Moriuchi, Koji Nagafuji, Yasuhiko Miyazaki, Source Type: research

A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with Β-Thalassemia Major
• Deferasirox up to 20 mg/kg/day significantly reduced serum ferritin in children with β-thalassemia major post-HSCT.• Deferasirox also decreased LIC and increased cardiac T2* levels.• Deferasirox was well tolerated with only 6 AEs requiring dose adjustment or interruption. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Mehmet Akif Yesilipek, Gulsun Karasu, Zuhre Kaya, Baris B. Kuskonmaz, Vedat Uygun, Ilkiz Dag, Onur Ozudogru, Mehmet Ertem Source Type: research

Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance Improving Their Hematopoietic-Supporting Ability
• Low dose of irradiation on human MSC improves their hematopoietic supporting-ability• Low-dose irradiation decreases the adipogenic differentiation of human MSC• Osteogenesis is increased after low-dose irradiation on human MSC (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Silvia Preciado, Sandra Munti ón, Ana Rico, Luis A. Pérez Romasanta, Teresa L. Ramos, Rebeca Ortega, Javier Borrajo, Luis A. Corchete, Concepción Rodríguez, María Díez-Campelo, Luis I. Sánchez-Abarca, María-Consuelo Del Cañizo, Fermín Sánchez-G Source Type: research

Kidney Pathology after Hematologic Cell Transplantation - a Single Center Observation Study of Indication Biopsies and Autopsies
• Cohort of 17 kidney biopsies and 137 autopsy kidneys of HCT patients• Membranous glomerulonephritis as putative correlate of chronic GvHD• Thrombotic microangiopathy occurs in different settings• Autopsy cases show findings otherwise rarely encountered in kidney biopsies• At autopsy, the majority of findings is related to the pre-agonal state of patients (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Michael Girsberger, J örg P. Halter, Helmut Hopfer, Michael Dickenmann, Thomas Menter Source Type: research

Treosulfan, Fludarabine Conditioning for HSCT in Children with Primary Immunodeficiency: UK Experience
• Excellent outcome in children post HSCT with treosulfan, fludarabine, for PID.• Better myeloid chimerism with PBSC. No increased acute GVHD grade III/IV or chronic GVHD.• 11 with SCID diagnosed at birth alive with up to 8.7 years follow up.• There was no veno- occlusive disease. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 16, 2017 Category: Hematology Authors: Mary A. Slatter, Kanchan Rao, Intan Juliana Abd Hamid, Zohreh Nademi, Robert Chiesa, Reem Elfeky, Mark S. Pearce, Persis Amrolia, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B. Gaspar, Andrew J. Cant, Andrew R. Genner Source Type: research

Epidemiological and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: a Prospective Single Center Study
• Human coronavirus are common after allogeneic stem cell transplantation, that they can progress to LRTDs, and in some cases, this leads to hospitalization and requires supportive care.• Human bocavirus are quite rare after allogeneic stem cell transplantation and are commonly detected in conju nction with other viral co-pathogens. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 15, 2017 Category: Hematology Authors: Jos é Luis Piñana, Silvia Madrid, Ariadna Pérez, Juan Carlos Hernández-Boluda, Estela Giménez, María José Terol, Marisa Calabuig, David Navarro, Carlos Solano Source Type: research

Success of Immunosuppressive Treatments in Patients with Chronic Graft-Versus-Host Disease
• After stopping therapy for cGVHD, half restarted after a median of 3.4 months• After 5.6 years, 1/3 each were still on IST, alive off IST, or dead/relapsed (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 10, 2017 Category: Hematology Authors: Stephanie J. Lee, Tam D. Nguyen, Lynn Onstad, Merav Bar, Elizabeth F. Krakow, Rachel B. Salit, Paul A. Carpenter, Morgani Rodrigues, A. Marcie Hall, Barry E. Storer, Paul J. Martin, Mary E. Flowers Source Type: research

Pediatric Hematopoietic Cell Transplant Patients Who Survive Critical Illness Frequently Have Significant but Recoverable Decline in Functional Status
• Survival with new functional morbidity is as prevalent an outcome as mortality.• New functional morbidity is recoverable in many patients.• Patients without functional recovery may be at-risk for in-hospital mortality. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 8, 2017 Category: Hematology Authors: M.S. Zinter, R. Holubkov, M.A. Steurer, C.C. Dvorak, C.N. Duncan, A. Sapru, R.F. Tamburro, P.S. McQuillen, M.M. Pollack Source Type: research

Transplant Decisions in Patients with Myelofibrosis: Should Mutations be the Judge?
• Current disease risk classifications are prognostic for post-transplant outcome.• Somatic mutations affect prognosis and should be included in the decision-making process regarding transplantation (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 8, 2017 Category: Hematology Authors: Rachel B. Salit, H. Joachim Deeg Source Type: research

Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: a Multicenter Cohort Study
• Prevalence of Venous thromboembolism (VTE) in patients undergoing Hematopoietic Cell Transplant (HCT) at tertiary care pediatric US hospitals is 7%.• Age ≥ 13 years and allogeneic transplants were significant associated risks factor for VTE.• In allogeneic recipients, Graft versus Host Dis ease (GvHD) and infections seen more frequently in patients with VTE. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 8, 2017 Category: Hematology Authors: Hemalatha G. Rangarajan, Joseph R. Stanek, Rolla Abu-Arja, Rajinder P.S. Bajwa, Jeffery J. Auletta, Dean A. Lee, Sarah H.O. Brien, Riten Kumar Source Type: research

Immunomodulatory Effects of Tyrosine Kinase Inhibitors (TKIs) in Vitro and in Vivo Study.
• TKIs suppress the production of pro-inflammatory cytokines in vitro, including IL17• TKIs reduce the frequency of total Tregs in vitro but preserve naïve subsets• B and NK cells are impaired by TKIs in vitro, whereas T cells are preserved• Comparable results were obtained in patients trea ted with Nilotinib for cGVHD (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 8, 2017 Category: Hematology Authors: Elena MARINELLI BUSILACCHI, Andrea COSTANTINI, Nadia VIOLA, Benedetta COSTANTINI, Jacopo OLIVIERI, Luca BUTINI, Giorgia MANCINI, Ilaria SCORTECHINI, Martina CHIARUCCI, Monica POIANI, Antonella POLONI, Pietro LEONI, Attilio OLIVIERI Source Type: research

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and CLL
• CD34 selected haploidentical cells are combined with Umbilical Cord Blood (haplo-cord) stem cells as donor source• Rapid neutrophil (median 11 days) and platelet recovery (19 days) is achieved because of the haplo-graft, but durable hematopoiesis resulting from the UCB graft with a very low in cidence of chronic GVHD (8%).• 42 patients with advanced lymphoma or CLL were treated and had 3-year OS, PFS and GRFS of 65%, 62% and 52% respectively. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 8, 2017 Category: Hematology Authors: Jingmei Hsu, Andrew Artz, Sebastian A. Mayer, Danielle Guarner, Michael R. Bishop, Ronit Reich-Slotky, Sonali M. Smith, June Greenberg, Justin Kline, Rosanna Ferrante, Adrienne A. Phillips, Usama Gergis, Hongtao Liu, Wendy Stock, Melissa Cushing, Tsiporah Source Type: research

PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-Versus-Host Disease in NOD-Scid IL-2Rynull Mice
• PRO 140 is a humanized monoclonal antibody targeting CCR5• Xeno-GvHD is produced when human BM is transplanted into immunocompromised mice• PRO 140 is effective at blocking xeno-GvHD• PRO 140 did not significantly alter bone marrow stem cell engraftment (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 8, 2017 Category: Hematology Authors: Denis R. Burger, Yvonne Parker, Kathryn Guinta, Daniel Lindner Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Source Type: research

Officers and Directors of ASBMT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Source Type: research

ASBMT Awards to be Presented at the 2018 BMT Tandem Meetings
The ASBMT is proud to announce the names of the award recipients who will be honored at the 2018 BMT Tandem Meetings this February in Salt Lake City. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Tags: ASBMT Notes Source Type: research

Table of contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Source Type: research

Poor Adherence is Associated with More Infections Following Pediatric Hematopoietic Stem Cell Transplant
• Poor oral medication adherence is prevalent and persistent among pediatric patients post-HSCT.• Among those patients receiving an allogeneic transplant, poor adherence to the outpatient medication regimen is associated with increased incidence of infections during the outpatient period. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Authors: Ahna L.H. Pai, Joseph Rausch, Sarah Drake, Caroline F. Morrison, Jennifer L. Lee, Adam Nelson, Alayna Tackett, Suzanne Berger, Lauren Szulczewski, Constance Mara, Stella Davies Source Type: research

Cellular Immunotherapy for Haematological Malignancies: Beyond Bone Marrow Transplant
• Cellular therapy is changing treatment options for malignant haematology• It has specific application in managing complications of bone marrow transplant• It can be used after failed bone marrow transplant or when it is unsuitable• Greater understanding of immunotherapy has helped differen tiate GVL effects• Barriers to translation include cost, access and limited Phase2/3 clinical trials (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - November 1, 2017 Category: Hematology Authors: Melita Cirillo, Peter Tan, Marian Sturm, Catherine Cole Source Type: research

Post-Transplant Cyclophosphamide (PTCY) as Sole GVHD Prophylaxis is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anaemia Using Matched Sibling Donors
• Post-transplant cyclophosphamide feasible in sibling donor transplants for SAA• Low incidence of acute and chronic GVHD• Low incidence of GVHD compared to cyclosporine and methotrexate• High incidence of viral infections seen (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 31, 2017 Category: Hematology Authors: Biju George, Nisham PN, Anup J. Devasia, Uday Kulkarni, Anu Korula, Kavitha M. Lakshmi, Aby Abraham, Alok Srivastava, Vikram Mathews Source Type: research

Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma – Comparison of Long Term Post Relapse Survival
We compared post-relapse overall survival (OS) after autologous-allogenenic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in multiple myeloma (MM). Post-relapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2000 and 2010 were analyzed. 404 patients (72.4%) relapsed in the auto/auto group and 178 patients (67.4%) relapsed in the auto/allo group after a median follow up of 8.5 years. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 25, 2017 Category: Hematology Authors: Myo Htut, Anita D'Souza, Amrita Krishnan, Benedetto Bruno, Mei-Jie Zhang, Mingwei Fei, Miguel Angel Diaz, Edward Copelan, Siddhartha Ganguly, Mehdi Hamadani, Mohamed Kharfan-Dabaja, Hillard Lazarus, Cindy Lee, Kenneth Meehan, Taiga Nishihori, Ayman Saad, Source Type: research

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potential cure for a variety of malignant and nonmalignant diseases. However, the alloreactivity required for the graft-versus-leukemia effect is closely associated with graft-versus host disease (GVHD), which remains one of the main causes of transplantation-related mortality (TRM) after HSCT [1,2]. Acute GVHD (aGVHD) is staged and graded according to symptom severity in 3 main target organs: skin, liver, and the gastrointestinal tract [3,4], and first-line treatment remains high-dose corticosteroids, typically starting at 1 to 2  mg/kg/day [5]. (Source...
Source: Biology of Blood and Marrow Transplantation - October 23, 2017 Category: Hematology Authors: Lia Minculescu, Brian Thomas Kornblit, Lone Smidstrups Friis, Ida Schi ødt, Soeren Lykke Petersen, Niels Smedegaard Andersen, Henrik Sengeloev Source Type: research

Bone Marrow Harvest in Pediatric Sibling Donors: Role of Granulocyte Colony-Stimulating Factor Priming and CD34+ Cell Dose
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment option for many malignant and nonmalignant diseases in children. Donor hematopoietic stem cells may be harvested from bone marrow, cord blood, or peripheral blood depending on clinical scenario and donor availability. Although all 3 hematopoietic stem cell sources have proven successful, hematopoietic stem cells harvested from HLA-matched sibling bone marrow result in superior post-transplantation outcomes in children and thus are considered the gold standard [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 23, 2017 Category: Hematology Authors: Aimee Furey, Sonal Rastogi, Remi Prince, Zhezhen Jin, Elana Smilow, Courtney Briamonte, Justine M. Kahn, Yvette Tanhehco, Nita Patel, Diane George, James Garvin, Monica Bhatia, Prakash Satwani Source Type: research

“C-Reactive Protein Levels at Acute GVHD Diagnosis Predict Steroid-Refractory Disease, Treatment Related Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation”
• Co-existing inflammation contributes to the initial pathogenesis in acute GVHD• CRP levels at diagnosis of grade II-IV acute GVHD predict steroid refractory disease (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 23, 2017 Category: Hematology Authors: Lia Minculescu, Brian Thomas Kornblit, Lone Smidstrups Friis, Ida Schi ødt, Soeren Lykke Petersen, Niels Smedegaard Andersen, Henrik Sengeloev Source Type: research

Bone Marrow Harvest in Pediatric Sibling Donors: Role of G-CSF Priming and CD34+ Cell Dose
• Optimal CD34+ cell dose infused to attain GRFS in children with HLA matched sibling donors is 3-5x106/kg.• We found no significant relationship between the number of CD34+ cells infused and various clinically relevant outcomes (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 23, 2017 Category: Hematology Authors: Aimee Furey, Sonal Rastogi, Remi Prince, Zhezhen Jin, Elana Smilow, Courtney Briamonte, Justine M. Kahn, Yvette Tanhehco, Nita Patel, Diane George, James Garvin, Monica Bhatia, Prakash Satwani Source Type: research

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis
Graft-versus-host disease (GVHD) is a significant obstacle to successful allogeneic hematopoietic stem cell transplantation (allo-HSCT), a curative treatment for many hematologic malignancies. Acute GVHD occurs when alloreactive donor T cells recognize recipient antigens as foreign and attack host tissues, especially in the liver, gut, and skin. Despite standard prophylaxis, acute GVHD incidence rates are approximately 30% to 50% in related donor HLA-matched transplants and as high as 50% to 70% in unrelated donor transplants [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Alex Ganetsky, David L. Porter, Robert H. Vonderheide, Ran Reshef Source Type: research

Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma
Mantle cell lymphoma (MCL), a non-Hodgkin lymphoma with increasing incidence in elderly persons, males, and Caucasians, typically presents with advanced-stage disease (stage III/IV) and an aggressive clinical course [1,2]. Treatment intensification, including incorporation of high-dose cytarabine [3], maintenance rituximab [4,5], and consolidation with autologous stem cell transplantation (ASCT) [6], have been associated with improved progression-free survival (PFS). Based on these findings, first-line treatment for patients with advanced-stage MCL who can tolerate aggressive therapy typically includes induction immunochem...
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Yolanda D. Tseng, Philip A. Stevenson, Ryan D. Cassaday, Andrew Cowan, Brian G. Till, Mazyar Shadman, Solomon A. Graf, Ralph Ermoian, Stephen D. Smith, Leona A. Holmberg, Oliver W. Press, Ajay K. Gopal Source Type: research

Homeostatic γδ T Cell Contents Are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of γδ T Cell Subsets after Haploidentical Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potent therapeutic strategy that has been increasingly used in patients with hematologic malignancies. Over recent decades, various approaches have been used for graft manipulation to reduce the risk of graft-versus-host disease (GVHD) while maintaining the engraftment and graft-versus-leukemia effect [1,2]. One novel strategy of graft manipulation in the setting of haploidentical HSCT (haploHSCT), removal of donor αβ T and B cells, highlighted a potential role of γδ T cells in grafts, in addition to the roles of natural killer and mo...
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Zhilei Bian, Lan-Ping Xu, Qiang Fu, Mingrui Huo, Long Liu, Xiaosu Zhao, Xiao-Jun Huang, Jiangying Liu Source Type: research

Outcomes of Unrelated Donor Stem Cell Transplant with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease
Sickle cell disease (SCD) is a hemoglobinopathy affecting 1 in every 500 African American newborns and an estimated 100,000 persons in the United States [1]. Vascular occlusion caused by the sickled RBCs leads to decreased perfusion in target organs and manifests clinically as vaso-occlusive pain crisis, stroke (cerebral infarction), pulmonary restrictive disease, and pulmonary hypertension [2]. Despite advances in supportive care, including the use of hydroxyurea (HU), RBC transfusion, and iron chelation therapy, patients with SCD continue to experience considerable morbidity and mortality in their lifetime. (Source: Biol...
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Hemalatha G. Rangarajan, Rolla Abu-Arja, Vinita Pai, Gregory M.T. Guilcher, Sandeep Soni Source Type: research

Fluid: Too Much or Too Little —Transplant Mortality May Hang in the Balance
Despite the overall improvement in outcomes of allogeneic hematopoietic cell transplant (HCT), toxicity to other organs such as kidney, lung, and liver remain frequent complications and impact morbidity and mortality post-transplant. In their study Rondon et  al. [1] suggest another risk factor for mortality in this patient population: fluid overload. Their grading system is based on the severity of the fluid overload: grade 1, weight gain (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Sangeeta Hingorani Source Type: research

Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices
• Retrospective study of early versus ANC driven G-CSF in autologous PBSCT inpatients• G-CSF was empirically started on day +5 versus day +12 only if ANC (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Amrita D. Singh, Sapna Parmar, Khilna Patel, Shreya Shah, Tsiporah Shore, Usama Gergis, Sebastian Mayer, Adrienne Phillips, Jing-Mei Hsu, Ruben Niesvizky, Tomer M. Mark, Roger Pearse, Adriana Rossi, Koen van Besien Source Type: research

Homeostatic Γδ T-Cell Contents are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of Γδ T Subsets after Haploidentical Hematopoietic Transplantation
• The proportions of γδT subsets were preserved in PB grafts after G-CSF priming.• The abundant IFN-γ-production capacity of γδT was maintained post-mobilization.• Homeostatic donor γδT content correlated with the early γδT recovery after HSCT.• Day-30 Vδ1 recovery inversely correl ated with CMV reactivation in HSCT recipients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Zhilei Bian, Lan-Ping Xu, Qiang Fu, Mingrui Huo, Long Liu, Xiaosu Zhao, Xiao-Jun Huang, Jiangying Liu Source Type: research

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as GVHD Prophylaxis
• A pharmacodynamic assay that quantifies chemokine receptor blockade is described.• Chemokine receptor blockade insufficiency was predictive of worse clinical outcomes.• Baseline recipient T-cell CCR5 expression levels were also predictive of clinical outcomes. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Alex Ganetsky, David L. Porter, Robert H. Vonderheide, Ran Reshef Source Type: research

Total Body Irradiation is Safe and Similarly Effective to Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Patients
• There was no significant difference in PFS and OS for MCL patients that underwent TBI- versus BEAM-based conditioning.• 5-year PFS was 66% versus 52% (TBI versus BEAM); OS 82% versus 68%, respectively.• Early toxicity, non-relapse mortality, and secondary malignancies were similar between gr oups. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Yolanda D. Tseng, Philip A. Stevenson, Ryan D. Cassaday, Andrew Cowan, Brian G. Till, Mazyar Shadman, Solomon A. Graf, Ralph Ermoian, Stephen D. Smith, Leona A. Holmberg, Oliver W. Press, Ajay K. Gopal Source Type: research

Outcomes of Unrelated Donor Stem Cell Transplant with Post-Transplant Cyclophosphamide for Graft- Versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
• A myeloablative regimen with single dose of post-transplant CY for unrelated donor HSCT in SCD.• Engrafted patients maintained donor chimerism with no acute or chronic GVHD.• Patients were off immunosuppression within 6 months post-transplant. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Hemalatha G. Rangarajan, Rolla Abu-Arja, Vinita Pai, Gregory M.T. Guilcher, Sandeep Soni Source Type: research

Fluid: Too Much or Too Little – Transplant Mortality May Hang in the Balance.
In this study, Rondon, et  al, suggest another risk factor for mortality in this patient population is fluid overload1. Their grading system is based on the severity of the fluid overload, grade 1 weight gain (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Sangeeta Hingorani Source Type: research

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA Haploidentical Transplant with Post-Transplant Cyclophosphamide
Graft-versus-host disease (GVHD) is a major complication of allogeneic blood or marrow transplantation (BMT). Grades II to IV acute (a)GVHD occurs in 40% to 60% [1] and chronic (c)GVHD in 30% to 70% [2,3] of patients receiving HLA-matched sibling donor BMT using calcineurin inhibitor –based GVHD prophylaxis. aGVHD and cGVHD are leading causes of nonrelapse mortality (NRM) [4-9], but they also reduce quality of life as a result of end-organ damage and adverse effects related to immunosuppressive therapy [9-13]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 18, 2017 Category: Hematology Authors: Shannon R. McCurdy, Christopher G. Kanakry, Hua-Ling Tsai, Yvette L. Kasamon, Margaret M. Showel, Javier Bola ños-Meade, Carol Ann Huff, Ivan Borrello, William H. Matsui, Robert A. Brodsky, Richard F. Ambinder, Maria P. Bettinotti, Ephraim J. Fuchs, Gary Source Type: research

Grade II Acute GVHD and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Posttransplant Cyclophosphamide
• Grade II acute GVHD improves progression-free survival after haplo BMT• Grade II acute GVHD decreases relapse after haplo BMT• Higher nucleated cell graft dose improves survival after haplo BMT• Higher nucleated cell graft dose decreases relapse and grade III-IV acute GVHD (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 18, 2017 Category: Hematology Authors: Shannon R. McCurdy, Christopher G. Kanakry, Hua-Ling Tsai, Yvette L. Kasamon, Margaret M. Showel, Javier Bola ños-Meade, Carol Ann Huff, Ivan Borrello, William H. Matsui, Robert A. Brodsky, Richard F. Ambinder, Maria P. Bettinotti, Ephraim J. Fuchs, Gary Source Type: research

Anti –Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic cell transplantation that can result in long-term pain and disability and negatively impact quality of life [1]. In vitro and early clinical trial experiences suggest that imatinib may have modest activity in corticosteroid-refractory or -dependent cGVHD, especially its sclerotic manifestations [2-9]. A recent randomized, phase II, crossover study of imatinib or rituximab for cutaneous sclerotic cGVHD demonstrated a significant clinical response in 26% of patients initially treated with imatinib. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 16, 2017 Category: Hematology Authors: George L. Chen, Paul A. Carpenter, Raewyn Broady, Tara K. Gregory, Laura J. Johnston, Barry E. Storer, Jan H. Beumer, Jingxin Qiu, Kiara Cerda, Ryan Le, Joanne M. Otani, Hong Liu, Maureen A. Ross, Sally Arai, Mary E.D. Flowers, Philip L. McCarthy, David B Source Type: research

Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myelogenous Leukemia: A National Population-Based Cohort Study
Allogeneic hematopoietic cell transplantation (allo-HSCT) is a potentially curative treatment strategy for patients with acute myelogenous leukemia (AML) due to the antileukemic effects of cytotoxic conditioning regimens and to the immunologic graft-versus-leukemia effect mediated by donor T cells [1,2]. Until recently, cytogenetic risk classification was the most important criterion when selecting postremission risk-adapted therapy [3], including HSCT in first complete remission (CR1). Most patients achieving CR1 have intermediate-risk cytogenetics, but to date, no truly randomized study has been completed in these patien...
Source: Biology of Blood and Marrow Transplantation - October 16, 2017 Category: Hematology Authors: Lene Sofie Granfeldt Østgård, Jennifer L. Lund, Jan Maxwell Nørgaard, Mette Nørgaard, Bruno C. Medeiros, Bendt Nielsen, Ove Juul Nielsen, Ulrik Malthe Overgaard, Maria Kallenbach, Claus Werenberg Marcher, Anders Hammerich Riis, Henrik Sengeløv Source Type: research

Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: a National Population-Based Cohort Study
• In a nationwide AML cohort, HSCT improves survival compared to chemotherapy-only• The anti-leukemic effect of HSCT in CR1 reduces relapse rates and increase RFS• Both intermediate and adverse cytogenetic risk patients benefit from HSCT in CR1• Superior outcomes in younger ( (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 16, 2017 Category: Hematology Authors: Lene Sofie Granfeldt Østgård, Jennifer L. Lund, Jan Maxwell Nørgaard, Mette Nørgaard, Bruno C. Medeiros, Bendt Nielsen, Ove Juul Nielsen, Ulrik Malthe Overgaard, Maria Kallenbach, Claus Werenberg Marcher, Anders Hammerich Riis, Henrik Sengeløv Source Type: research

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations during Conditioning for Hematopoietic Stem Cell Transplantation
• Post ATG there is a high incidence of severe acute hepatotoxicity (SAH). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 16, 2017 Category: Hematology Authors: W.J.F.M. van der Velden, E.C. de Weerd-de Jong, A.F.J. de Haan, N.M.A. Blijlevens Source Type: research

Anti-PDGFRA Antibodies Predict for Response to Nilotinib in Steroid Refractory / Dependent cGvHD
• Nilotinib has clinical activity in steroid refractory / dependent cGvHD.• Anti-PDGFRA antibodies may predict which patients respond to nilotinib. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 16, 2017 Category: Hematology Authors: George L. Chen, Paul A. Carpenter, Raewyn Broady, Tara K. Gregory, Laura J. Johnston, Barry E. Storer, Jan H. Beumer, Jingxin Qiu, Kiara Cerda, Ryan Le, Joanne M. Otani, Hong Liu, Maureen A. Ross, Sally Arai, Mary E.D. Flowers, Philip L. McCarthy, David B Source Type: research

Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation
• Dysgeusia is a pervasive and complex complication of hematopoietic-cell transplantation.• It has an impact upon many factors such as oral diet, quality of life, physical, and immunologic recovery.• Innovative studies are required to understand its pathobiology, and to manage dysgeusia after HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - October 16, 2017 Category: Hematology Authors: Michael Scordo, Gunjan Shah, Jonathan U. Peled, Elaina Preston, Marissa Buchan, Joel B. Epstein, Andrei Barasch, Sergio Giralt Source Type: research